共 8 条
[1]
Guidelinesfor the Managemenf of Adults with Community-acquired Pneu-monia. Niedeman MS,,Mandell LA,Anzueto A,et al. American Journal of Respiratory and Critical Care Medicine . 2001
[4]
Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Heffelfinger JD,Dowell SF,Jorgensen JH,et al. Archives of Internal Medicine . 2000
[5]
Tissue-directed pharmacokinetics. Jerome J. Schentag Pharm.D. and Charles H. Ballow Pharm.D. The American Journal of Medicine . 1991
[6]
Efficacy and safe-ty of3-day azithromycin versus5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchi-tis. Zervos M,Martinez FJ,Amsden GW,et al. International Journal of Antimicrobial Agents . 2007
[7]
Azithromycin extended re-lease:a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US. Swainston Harrison T,Keam SJ. Drugs . 2007
[8]
Clinical implications of macrolide re-sisitance in community-acquired respiratory tract infections. Hoban DJ,Zhanel GG. Expert Rev Anti Infect Ther . 2006